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Introduction

Dolutegravir (DTG) is an integrase inhibitor of human immunodeficiency virus (HIV)
. DTG chelates the divalent metal cations in the integrase catalytic site of HIV virus through the three coplanar oxygen atoms in the structure, thereby blocking viral replication [1] . DTG has been considered a new generation HIV integrase inhibitor with a better resistance profile compared to the first generation integrase inhibitors [2, 3] . DTG possesses prolonged binding to the integrase-DNA complex, and thus has a higher genetic barrier to resistance [4] . Based on its lower risk of resistance acquisition, DTG, together with nucleoside reverse transcriptase inhibitors, is a recommended regimen for persons infected with HIV [5, 6] .
The clinical pharmacokinetics of DTG is favorable in healthy volunteers, with rapid absorption, low clearance and relative long oral terminal half-life [7] . In a mass balance study of DTG, the predominant circulating component identified in plasma was DTG, and 31.6% and 64.0% of the administrated dose was recovered in urine and feces, respectively [8] . The most abundant metabolites of DTG were the ether glucuronide followed by a benzylic hydroxylated metabolite and its hydrolytic product [9] . UDP-glucuronosyltransferase (UGT) 1A1 and cytochrome P450 (CYP) 3A4 are the two key enzymes contributing to the ether glucuronidation and benzylic oxidation of DTG, respectively [10] .
The effects of intrinsic and extrinsic factors on DTG pharmacokinetics have been examined in a population pharmacokinetic analysis using combined data from three clinical trials in persons with HIV infection, including smokers. It was found that the clearance of DTG was higher in current smokers than non-smokers [11] . However, the exact mechanism for this difference is unclear. The induction of metabolic enzymes responsible for DTG metabolism by cigarette smoking may be the reason for this pharmacokinetic difference. Cigarette smoking has been found to induce CYPs, including CYP1A1, 1A2, 1B1, 2B6 and 2E1 [12] [13] [14] , but its influence on CYP3A4 is minor [15] . The current study re-profiled the metabolic pathways of DTG using a metabolomic approach. The enzymes that contribute to DTG metabolism were profiled using recombinant human CYPs.
Materials and methods
Chemicals and reagents
DTG, methoxyamine (NH 2 OMe), isoniazid (INH), dimethyl sulfoxide (DMSO), corn oil and semicarbazide were purchased from SigmaAldrich (St. Louis, MO). 2,4-Difluorobenzaldehyde was purchased from TCI America (Portland, OR). β-nicotinamide adenine dinucleotide phosphate (NADPH) and 2,3′,4,5′-tetramethoxystilbene (TMS) were purchased from Alfa Aesar (Tewksbury, MA) and Cayman (Ann Arbor, MI), respectively. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was purchased from Toronto Research Chemical (Toronto, Ontario). Human liver microsomes (HLM) and the recombinant human CYPs (EasyCYP Bactosomes) were purchased from XenoTech (Lenexa, KS). All solvents for ultra-performance liquid chromatography and quadrupole time-offlight mass spectrometry (UPLC-QTOFMS) analysis were of the highest grade commercially available.
Metabolism of DTG in HLM
Incubations were carried out in 1 × phosphate-buffered saline (PBS, pH 7.4), containing HLM (1.0 mg/mL), 30 µM DTG and 1.0 mM NADPH in a final volume of 100 µL. In addition, co-incubation with the trapping agent 2.5 mM NH 2 OMe or semicarbazide was performed. The groups in the absence of NADPH, DTG, or NH 2 OMe were used as controls. The reactions were continued at 37°C for 1 h with gentle shaking. The reactions were terminated by adding 100 µL methanol/acetonitrile (1:1, v/v). The mixture was vortexed for 1 min and centrifuged at 15,000 rpm for 10 min. Five μL of the supernatant was injected into the UPLC-QTOFMS system for metabolite analysis. All incubations were performed in triplicate.
Metabolism of DTG by recombinant human CYPs
Incubations were conducted in 1 × PBS (pH 7. In addition, co-incubations of the inhibitor TMS at 10 μM and 500 nM with CYP1A1 and 1B1, respectively, were performed to confirm the roles of CYP1A1 and 1B1 in DTG metabolism. All incubations were carried out at 37°C for 1 h, and the reactions were terminated with 200 µL of methanol. The mixture was then vortexed and dried, and further reconstituted in 100 µL of water/ acetonitrile/methanol (1:2:2, v/v/v). The suspension was vortexed for 1 min and centrifuged at 15,000 rpm for 10 min. A 10 μL of the supernatant was injected into the UPLC-QTOFMS system for metabolite analysis. The K m values for CYP1A1 and 1B1 were calculated using Graphpad Prism 6.
DTG metabolism in lung S9 from mice treated with TCDD
Following Harrigan's protocol [16] , C57BL/6 mice (male, 7-8 weeks old) were treated with TCDD (5 μg/kg, 2% DMSO in corn oil, i.p.) or vehicle (n = 4). Forty-eight hours later, all mice were sacrificed and lung samples were harvested. Lung tissues were flash-frozen in liquid nitrogen and stored at −80°C until further analysis. The study protocol was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. One hundred mg of lung tissue was homogenized in 500 μL of 1 × PBS at 0°C. The homogenate was centrifuged at 9,000g for 25 min at 4°C and the resulting supernatant was designated as lung S9 fraction. The total protein concentration of the S9 fraction was determined by bovine serum albumin standard (Thermo Fisher, Waltham, MA) calibration curves. Incubations were conducted in 1 × PBS (pH 7.4), containing 30 µM DTG, 2.5 mM NH 2 OMe, 2 mg/ mL lung S9, and 1 mM NADPH in a final volume of 200 µL. The incubations were continued at 37°C for 1 h, and terminated with 200 µL of methanol. The resulting mixture was vortexed and dried, and reconstituted in 100 µL of water/acetonitrile/methanol (1:2:2, v/v/v). The suspension was vortexed and centrifuged at 15,000 rpm for 10 min. A 10 μL of the supernatant was injected into the UPLC-QTOFMS system for metabolite analysis.
Quantitative real-time polymerase chain reaction (qPCR) for analysis of Cyb1a1 and 1b1
Total RNA was extracted from approximately 40 mg of frozen lung tissue using TRIzol reagent (Invitrogen, Carlsbad, CA), and subjected to reverse transcription with random hexamer primers and M-MLV RT (Invitrogen). qPCR using SYBR green PCR master mix was performed with the ABI7500 System. All data was normalized against the cyclophilin control.
UPLC-QTOFMS analysis
Chromatographic separation of metabolites was performed on an Acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 µm; Waters Corporation, Milford, MA). The mobile phase A was 0.1% formic acid in water, and the mobile phase B was 0.1% formic acid in acetonitrile. The elution gradient was set as follows: 0.0-1.0 min, 2% B; 1.0-9.0 min, 2-95% B; 9.0-13.5 min, 95% B; 13.5-13.6 min, 95-2% B; 13.6-15 min, 2% B. The flow rate of the mobile phase was 0.5 mL/min and the column temperature was maintained at 50°C. The QTOFMS system was operated in a positive high-resolution mode with electrospray ionization [17] . To maximize the class discrimination, partial least squares- discriminant analysis (PLS-DA) was conducted using SIMCA-P software (Version 13, Umetrics, Kinnelon, NJ). DTG metabolites were identified by the corresponding S-plot based on accurate mass measurement (mass errors less than 10 ppm) and MS/MS fragmental analysis.
Statistical analysis.
Data are expressed as means or means ± SD. Statistical analyses were performed with two-tailed Student's t-test and a p value < 0.05 was considered as statistically significant.
Results
Identification of M1, M2, and M3
Three groups of DTG incubations were well separated to the corresponding clusters by PLS-DA analysis (Fig. 1A) . The top ranking ions labeled in the upper-right quadrant of the S-plot were identified as DTG and its metabolites M1, M2 and M3 (Fig. 1B) . These three metabolites were only detected in the incubation group with HLM and NADPH, suggesting they are produced in CYP-dependent pathways. The chromatograms of M1, M2 and M3 are shown in Fig. 1C . M1 has a protonated molecular ion [M + H] at m/z = 294.1075 Da, which indicates the loss of the 2,4-diflurobenzyl moiety. MS/MS fragmental ions of M1 at m/z = 277, 249, and 177 confirmed the N-dealkylated structure ( Fig. 2A) . Based on the protonated molecular ion [M + H] at m/ z = 418.1398 Da, M2 was identified as an oxidative defluorination metabolite. The primary MS/MS fragmental ions of M2 were found at m/z 294, 277 and 125 (Fig. 2B) . The ion at m/z 125 in M2 indicated the loss of a fluorine atom and addition of an oxygen atom. The accurate molecular weight revealed M3 was an oxidized DTG metabolite. The major MS/MS fragmental ions of M3 were found at m/z 294, 277 and 143 (Fig. 2C) . The MS/MS fragmental ion at m/z 143 in M3 suggested the oxidation occurred at the phenyl part of DTG (Fig. 2C) . Both M2 and M3 have the fragmental ion at m/z 294, the same mass as M1 (Fig. 2) . Therefore, when we extracted the chromatogram of M1 at m/z 294, all peaks at m/z 294 showed up, which came to be the small peaks within M2 and M3 (Fig. 1C) .
Identification of M4
To recapture possible production of aldehyde, NH 2 OMe was used as a trapping agent [18] . Four groups of incubation were well-separated in the PLS-DA score plot (Fig. 3A) . The trend plot showed that M4-NH 2 OMe was present only in the DTG_HLM_NH 2 OMe_NADPH group (an incubation system containing DTG, HLM, NH 2 OMe, and NADPH), suggesting its production is CYP-dependent (Fig. 3B) . M4-NH 2 OMe was eluted at 4.40 min (Fig. 3C) with the major MS/MS fragmental ions at m/z 447, 392, 366, 322, 249, 223, 206 and 127 (Fig. 3D) . The fragmental ions at m/z 127 and 322 demonstrated that the 2,4-difluorophenyl group was intact, and the oxime structure appeared at the left region in DTG. Fragmental ions at m/z 392 and 249, typical peaks formed by McLafferty rearrangement of the oxime moiety, indicated that the oxidation occurred at the adjacent position of the oxygen atom rather than the nitrogen atom in DTG's oxazine ring. To further confirm M4 as an aldehyde, semicarbazide [19] was used as another trapping agent. As expected, the corresponding oxime was detected (Fig. 4A) , and the MS/MS fragmental pattern of M4-semicarbazide is similar to that of M4-NH 2 OMe (Fig. 4B). 
Role of CYPs in the formation of M1, M2 and M3
CYP3A4 has been found to be important in M1 formation [10] . However, the current study found that CYP1A1 and 1B1 are more efficient than CYP3A4 in M1 production in the incubation of DTG at 30 μM (Fig. 5A-C) . DTG itself is a weak CYP3A4 inhibitor [10] . To avoid potential inhibition of CYP3A4, incubations with a lower concentration of DTG (5 μM) were conducted, and the results were similar to that of DTG at 30 μM (Fig. 5B) . The roles of CYP1A1, 1B1 and 3A4 in M1 formation were further investigated by profiling the enzymatic kinetics of M1 production with DTG concentration up to 300 μM (Fig. 5C ). The K m values of CYP1A1 and 1B1 for M1 formation were 41.4 μM and 97.1 μM, respectively. M1 formation was decreased in the incubation with CYP3A4 and DTG at 300 μM, due to CYP3A4 inhibition by DTG (Fig. 5D) . Furthermore, co-incubation of DTG with TMS, a CYP1A1 and 1B1 inhibitor [20] , significantly decreased M1 production (Fig. 5E) , which confirmed the roles of CYP1A1 and 1B1 in M1 production. Nevertheless, CYP3A4 and 3A5 were the major enzymes contributing to the formation of M2 and M3 in DTG metabolism (Fig. 6) .
Identification of M5
Theoretically, besides M1, another hydrolytic product of M3 should be 2,4-difluorobenzaldehyde (M5). However, M5 was not identified when NH 2 OMe was used as a trapping regent. Direct incubation of NH 2 OMe with M5 standard was performed, but no oxime was detected, which may be related to the weak reaction activity of NH 2 OMe with M5 or low detection sensitivity of the M5-NH 2 OMe oxime. INH contains a hydrazine group that has a high reactivity with aldehyde products [21] . Through incubation of INH with M5 standard, M5-INH adduct was identified (Fig. 7A) . The MS/MS fragmental ions of M5-INH were at m/z 214, 142, 121, 105 and 80 (Fig. 7B) . The ions at 142 and 121 indicated the 2,4-difluorophenyl ring and isonicotinamide moiety, respectively. The detection limit of M5 by trapping with INH could be as low as 1 nM (Fig. 7C) . Based on the roles of CYPs in M1 formation (Fig. 5) , the key CYPs responsible for M5 production should be CYP1A1 and 1B1. Indeed, M5-INH could be detected in the incubation of DTG with CYP1A1 and 1B1 (Fig. 7D) , and the abundance of M5-INH was consistent with M1 production (Fig. 7E) .
Roles of CYP1A1 and 1B1 in M4 formation
The major CYPs contributing to M4 formation were found to be CYP1A1 and 1B1 (Fig. 8A) . The enzymatic kinetics of M4 formation was investigated in the incubations of DTG with CYP1A1 and 1B1. The estimated K m values of CYP1A1 and 1B1 for M4 formation were 103.5 μM and 127.5 μM, respectively (Fig. 8B) . The kinetics of M4 formation in CYP3A4 was similar to M1 (Fig. 5C and D) , which showed a minor role in M4 production and a decline at 300 μM of DTG (data not shown). Furthermore, the roles of CYP1A1 and 1B1 in M4 formation were confirmed using TMS, which significantly inhibited M4 production (Fig. 8C) .
Induction of CYP1A1 and 1B1 boosts the formation of M1 and M4
TCDD is a strong inducer of CYP1A1 and 1B1 [22, 23] . As expected, pretreatment of mice with TCDD significantly increased the expression of Cyp1a1 and 1b1 in mouse lung (Fig. 9A) . Compared to the vehicle group, the productions of M1 and M4 were significantly increased in the lungs of mice treated with TCDD ( Fig. 9B and C) . The increased productions of DTG metabolites were consistent with the upregulation of Cyp1a1 and 1b1 in the TCDD group. In addition, TMS significantly suppressed the formation of M1 and M4 in the lung, which further confirmed the roles of CYP1A1 and 1B1 in M1 and M4 production ( Fig. 9B and C) .
Discussion
Using a metabolomics approach, the current study uncovered the CYP1A1 and 1B1-mediated metabolic pathways of DTG (M1 and M4) (Fig. 10) . The current study also found that CYP1A1 and 1B1-mediated metabolism of DTG can produce two aldehydes (M4 and M5) (Fig. 10) . In addition, CYP1A1 and 1B1 are found to be more efficient than CYP3A4 in M1 and M4 production.
Both CYP1A1 and 1B1 are extrahepatic CYPs [24] . CYP1A1 is primarily found in the respiratory system, while CYP1B1 is more widely expressed in extrahepatic tissues [25, 26] . CYP1A1 and 1B1 are involved in the metabolism of multiple pro-carcinogens including polycyclic aromatic hydrocarbons (PAHs) from tobacco and environmental exposure [12] . On the other hand, PAHs can induce the expression of CYP1A1 and 1B1 through an aryl hydrocarbon receptor (AhR)-dependent mechanism [27] . Indeed, the expressions of CYP1A1 and 1B1 in the lung are significantly upregulated in smokers compared to nonsmokers [28] . Besides CYP1s, cigarette smoking also induces CYP2B6 and CYP2E1 [14, 29] , but neither CYP2B6 nor CYP2E1 is involved in DTG metabolism (Figs. 5, 6 , and 8). Although nicotine, a dominant alkaloid in cigarette, is reported to be an activator of pregnane X receptor that upregulates CYP3A4 expression [30] , the pharmacokinetic parameters of midazolam, a classical CYP3A4 probe drug, are not significantly different between smokers and non-smokers [15] . These data suggest that cigarette smoking could alter DTG metabolism by inducing CYP1A1 and 1B1, but not other CYPs.
TCDD is a potent AhR ligand that can strongly induce the expression of CYP1A1 and 1B1 [27] . The current study found that CYP1A1 and 1B1-dependent production of DTG metabolites (M1 and M4) were dramatically increased in the lungs of mice treated with TCDD. Interestingly, DTG is highly distributed in the lung after DTG treatment [9] . The high pulmonary exposure to DTG together with the highly induced CYP1A1 and 1B1 in the lung of smokers will increase DTG metabolism, and therefore increase the clearance of DTG. Additionally, brain reservoirs is an obstacle for HIV cure [31] in part due to the poor local concentrations of anti-HIV drugs in the brain. Because CYP1A1 and 1B1 are expressed in the brain [32] , cerebral DTG concentration would be decreased by CYP1 induction and thereby negatively influences therapeutic outcomes.
Although DTG displayed a favorable safety profile in clinical trials, discontinuation rates of DTG was higher than expected in real-life settings [33, 34] . The major reported adverse event of DTG is neurotoxicity [35] , and the underlying mechanism is unclear. Both M4 and M5 are aldehyde metabolites of DTG and they are produced by CYP1A1 and 1B1 (Fig. 10) . Aldehyde, a hard electrophile, can covalently bind with hard nucleophiles, such as lysine residues in proteins, which can cause protein dysfunction and potentially lead to toxicity [36] . Considering the expression of CYP1A1 and 1B1 in the brain [32] , further investigation is warranted to examine the potential contribution of CYP1A1 and 1B1-mediated production of aldehydes to DTG neurotoxicity.
In summary, the current study identified two CYP1A1 and 1B1-mediated pathways in DTG metabolism (M1 and M4) (Fig. 10) . Induction of CYP1A1 and 1B1 can significantly accelerate the metabolic pathways of M1 and M4. These data suggest that persons with HIV receiving DTG should be cautious to cigarette smoking, drugs, and environmental chemicals that activate AhR and induce CYP1A1 and 1B1.
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